without or with AAV6 vectors carrying the AAVS1-GFP or CCR5-GFP donor at 1 X 10 6 vg/cell for 16 hours and/or electroporated with 20 ug/ml AAVS1 or 40ug/ml CCR5 ZFN mRNA. Cells were expanded and analyzed 9 days post-electroporation by flow cytometry. (A) One set of representative FACS plots are shown. (B) Results (mean ± SD) are from triplicated samples except the "AAVS1 ZFN, no donor" and "CCR5 ZFN, no donor" treatment conditions. * P < 0.05, one-way ANOVA. The %GFP+ detected in samples treated with "No ZFN, AAVS1-GFP donor" (1.03 ± 0.04%) and "No ZFN, CCR5-GFP donor" (0.76 ± 0.21%) represent GFP expression from episomal DNA (i) and random integration (ii) of AAV genome. The difference (3.54%) between "CCR5 ZFN + AAVS1-GFP donor" (4.57 ± 0.36%) and "No ZFN, AAVS1-GFP donor" (1.03 ± 0.04%) represent end capture (integration of AAV genome at a double-strand break site in cellular genome) mediated by CCR5 ZFN cleavage (iii & iv) . The majority of the 3.54% are presumably located at the CCR5 on-target site (iii). A small portion of the 3.54% are presumably located at some offtarget sites (iv). The difference (55.38%) between "AAVS1 ZFN + AAVS1-GFP donor" (58.13 ± 1.89%) and "AAVS1 ZFN + CCR5-GFP donor" (2.75 ± 0.40%) represent HDR (v). The difference (1.99%) between "AAVS1 ZFN + CCR5-GFP donor" (2.75 ± 0.40%) and "No ZFN, CCR5-GFP donor" (0.76 ± 0.21%) represent end capture mediated by AAVS1 ZFN cleavage (iii & iv). The majority of the 1.99% are presumably located at the AAVS1 on-target site (iii). A small portion of the 1.99% are presumably located at some off-target sites (iv). The difference (45.34%) between "CCR5 ZFN + CCR5-GFP donor" (49.91 ± 1.97%) and "CCR5 ZFN + AAVS1-GFP donor" (4.57 ± 0.36%) represent HDR (v). Forward primer sequence is preceded by 5'-ACACGACGCTCTTCCGATCTNNNN.
Supplementary
Reverse primer sequence is preceded by 5'-GACGTGTGCTCTTCCGATCT. 
GTCATGCTCTTCAGCCTTTTGCAGTT---------GAGGATGACCAGCATGTTGCCCAC 12 0.33 +4bp
GTCATGCTCTTCAGCCTTTTGCAGTTT--CAGGATGAGGATGACCAGCATGTTGCCCAC 14 0.25 +2bp Supplementary Table S2 . CD8 + T cells were transduced with 1 X 10 6 vg/cell AAV6 vectors carrying the CCR5-RFLP donor for 16 hours, then electroporated with CCR5 ZFN mRNA (60 μg/ml). Cells were analyzed 7 days post-electroporation by deep sequencing to measure the efficiency of genome modification (% indels and RFLP HDR). The top 20 sequences from a treated sample were aligned against the wild-type CCR5 sequence. Only the most important portion of the sequences is shown. In sequence alignment, CCR5 ZFN binding sites are underlined. Deleted bases are indicated by "-". Inserted bases are indicated in red color. *One representative sequence for each type of alignment is shown. TTTATCTGTCCCCTCCACCCCACAGTGGG----------ACAGGATTGGTGACAGAAAAGCCC 4 1.77 +4bp
TTTATCTGTCCCCTCCACCCCACAGTG-----ACTAGGGACAGGATTGGTGACAGAAAAGCCC 
TTTATCTGTCCCCTCCACCCC---------------------------------GAAAAGCCC
Supplementary Table S3 . CD8 + T cells were transduced with 3 X 10 5 vg/cell AAV6 vectors carrying the AAVS1-RFLP donor for 16 hours, then electroporated with AAVS1 ZFN mRNA (40 μg/ml). Cells were analyzed 7 days post-electroporation by deep sequencing to measure the efficiency of genome modification (% indels and RFLP HDR). The top 20 sequences from a treated sample were aligned against the wild-type AAVS1 sequence. Only the most important portion of the sequences is shown. In sequence alignment, AAVS1 ZFN binding sites are underlined. Deleted bases are indicated by "-". Inserted bases are indicated in red color. *One representative sequence for each type of alignment is shown.
